Stephen A Sherwin insider trades: Neurocrine Biosciences (NBIX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Stephen reports to the SEC
and 3 more companies
Open-market buys and sales
19 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 5, 2026 | NBIX | ↓ Sell | 25,000 | $165.32 | $4.1M | Direct | Jun 9, 2026 (4d) |
| Mar 7, 2025 | BIIB | ↓ Sell | 8,760 | $150.02 | $1.3M | Direct | Mar 10, 2025 (3d) |
| Feb 13, 2025 | NBIX | ↓ Sell | 13,831 | $116.69 | $1.6M | Direct | Feb 14, 2025 (1d) |
| May 29, 2024 | NBIX | ↓ Sell | 40,000 | $133.46 | $5.3M | Direct | May 30, 2024 (1d) |
| Jan 3, 2023 | NBIX | ↓ Sell | 30,000 | $118.86 | $3.6M | Direct | Jan 5, 2023 (2d) |
| Jan 24, 2022 | NBIX | ↓ Sell | 15,000 | $74.43 | $1.1M | Direct | Jan 26, 2022 (2d) |
| Apr 28, 2020 | NBIX | ↓ Sell | 17,687 | $99.39 | $1.8M | Direct | Apr 30, 2020 (2d) |
| Mar 11, 2020 | BIIB | ↓ Sell | 2,434 | $295.22 | $719K | Direct | Mar 12, 2020 (1d) |
| Jun 11, 2018 | NBIX | ↓ Sell | 10,000 | $98.44 | $984K | Direct | Jun 13, 2018 (2d) |
| Mar 10, 2015 | BIIB | ↓ Sell | 6,000 | $409.67 | $2.5M | Direct | Mar 11, 2015 (1d) |
| Dec 26, 2014 | VSTM | ↑ Buy | 2,500 | $8.56 | $21K | Through Sherwin Family Trust | Dec 29, 2014 (3d) |
| Jan 2, 2014 | BIIB | ↓ Sell | 5,500 | $279.28 | $1.5M | Direct | Jan 6, 2014 (4d) |
| Jun 3, 2013 | BIIB | ↓ Sell | 12,825 | $233.26 | $3.0M | Direct | Jun 4, 2013 (1d) |
| May 23, 2013 | VICL | ↑ Buy | 7,003 | $0.01 | $70 | Direct | May 28, 2013 (5d) |
| Mar 22, 2013 | BIIB | ↓ Sell | 1,500 | $176.88 | $265K | Direct | Mar 25, 2013 (3d) |
| Sep 4, 2012 | BIIB | ↓ Sell | 2,000 | $145.90 | $292K | Direct | Sep 5, 2012 (1d) |
| Jun 4, 2012 | BIIB | ↓ Sell | 2,500 | $126.45 | $316K | Direct | Jun 5, 2012 (1d) |
| Dec 19, 2011 | BIIB | ↓ Sell | 2,500 | $110.88 | $277K | Direct | Dec 20, 2011 (1d) |
| Jun 8, 2005 | CEGE | ↑ Buy | 2,500 | $4.96 | $12K | Direct | Jun 8, 2005 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other NBIX insiders
Open-market trades in the last 12 months
About Stephen A Sherwin's insider trades
Stephen A Sherwin is a director at Neurocrine Biosciences (NBIX). Since Jun 8, 2005, Stephen has reported 3 open-market purchases worth $34K and 16 sales worth $28.7M on SEC Form 4. In the last 12 months: 1 sale ($4.1M).
Their filings also include grants and awards (75 filings), option exercises (17 filings), gifts (12 filings), shares withheld for taxes (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NBIX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.